Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18964137 | PLASMID ENCODING A DNAse-I AND Fc FUSION PROTEIN | November 2024 | August 2025 | Allow | 8 | 2 | 0 | No | No |
| 18964119 | PLASMID ENCODING A TLR9 AND Fc FUSION PROTEIN | November 2024 | October 2025 | Allow | 11 | 2 | 0 | No | No |
| 18964155 | PLASMID ENCODING A NGF AND Fc FUSION PROTEIN | November 2024 | December 2025 | Allow | 12 | 2 | 0 | No | No |
| 18964162 | PLASMID ENCODING AN INSULIN PEPTIDE AND Fc FUSION PROTEIN | November 2024 | December 2025 | Allow | 12 | 2 | 0 | No | No |
| 18633883 | TRANSGENIC RAINBOW SHARK | April 2024 | October 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18582222 | PLASMID ENCODING A TLR3 AND Fc FUSION PROTEIN | February 2024 | August 2025 | Allow | 17 | 3 | 2 | Yes | No |
| 18415134 | COMPUTER-BASED SYSTEMS FOR CONTROLLING AND MONITORING METABOLIC RATE AND ENVIRONMENTAL FACTORS OF AT LEAST ONE BIOREACTOR AND METHODS OF USE THEREOF | January 2024 | December 2025 | Abandon | 23 | 1 | 1 | Yes | No |
| 18526459 | GENERATING ATRIAL AND VENTRICULAR CARDIOMYOCYTE LINEAGES FROM HUMAN PLURIPOTENT STEM CELLS | December 2023 | July 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18521129 | Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof | November 2023 | January 2026 | Abandon | 26 | 1 | 0 | No | No |
| 18511290 | AAV CAPSIDS WITH INCREASED TROPISM TO BRAIN TISSUE | November 2023 | October 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18450896 | MULTIPOTENT ADULT STEM CELLS: CHARACTERIZATION AND USE | August 2023 | November 2025 | Abandon | 27 | 2 | 1 | Yes | No |
| 18450549 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | August 2023 | June 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18339917 | TRAIT SELECTION IN AVIANS | June 2023 | October 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18316461 | GENETICALLY MODIFIED MICE HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18309466 | ETV2 AND USES THEREOF | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18250609 | Barcoded Cells Engineered With Heterozygous Genetic Diversity | April 2023 | February 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18192492 | METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 | March 2023 | March 2025 | Allow | 24 | 2 | 0 | No | No |
| 18246231 | METHODS FOR TREATING CANCER AND AUTOIMMUNE AND INFLAMMATORY DISEASES | March 2023 | December 2025 | Abandon | 33 | 4 | 1 | No | No |
| 17767391 | NON-HUMAN ALZHEIMER'S DISEASE MODEL ANIMAL AND METHOD FOR PRODUCING SAME | March 2023 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 18177718 | ANTI-IGF-I RECEPTOR ANTIBODY | March 2023 | November 2025 | Abandon | 33 | 2 | 0 | No | No |
| 18175010 | METHOD OF USING A GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMAN ALBUMIN | February 2023 | February 2025 | Allow | 23 | 2 | 0 | No | No |
| 18162850 | GUIDE RNA FOR REPAIRING A MUTANT HUMAN TITIN GENE USING CRISPR TECHNOLOGY | February 2023 | July 2025 | Allow | 29 | 2 | 1 | No | No |
| 18159414 | MOUSE MODEL OF DITRA DISEASE AND USES THEREOF | January 2023 | July 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18091888 | WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS WITH NUCLEAR REPROGRAMMING FACTORS | December 2022 | March 2026 | Abandon | 39 | 2 | 0 | No | Yes |
| 18085420 | METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION OF TRANSGENES INTO MAMMALIAN LIVER CELLS | December 2022 | July 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18009187 | POULTRY CELL IN WHICH A GENE ENCODING A PROTEIN OF INTEREST IS KNOCKED-IN AT EGG WHITE PROTEIN GENE, AND METHOD FOR PRODUCING SAID POULTRY CELL | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17993717 | METHODS OF CYTOTOXIC GENE THERAPY TO TREAT TUMORS | November 2022 | July 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17919278 | ARTIFICIAL ONCOLYTIC VIRUSES AND RELATED METHODS | October 2022 | March 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17800348 | GENETICALLY MODIFIED MOUSE WITH A DISRUPTION IN AN AANAT GENE | August 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17884069 | CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS | August 2022 | November 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17882395 | PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS | August 2022 | November 2025 | Abandon | 40 | 6 | 0 | Yes | No |
| 17882314 | PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS | August 2022 | March 2026 | Abandon | 43 | 7 | 0 | Yes | No |
| 17814791 | METHODS OF PRODUCING HUMAN FOREGUT ENDODERM CELLS EXPRESSING PDX1 FROM HUMAN DEFINITIVE ENDODERM | July 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17814388 | GENETICALLY MODIFIED T CELL RECEPTOR MICE | July 2022 | August 2024 | Abandon | 25 | 3 | 0 | Yes | Yes |
| 17812342 | VIABLE GENETICALLY MODIFIED SHEEP WITH AN INACTIVATED ALPHA-1,3-GALACTOSYLTRANSFERASE (GGTA1) GENE | July 2022 | January 2025 | Allow | 31 | 4 | 1 | No | No |
| 17811089 | NUCLEIC ACIDS COMPRISING A MODIFIED RODENT ACTIVIN A RECEPTOR TYPE 1 (ACVR1) GENE | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17854286 | Adeno-Associated Virus Factor VIII Vectors | June 2022 | October 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17809219 | PROCESS FOR USING CRISPR TO TRANSFECT PRIMORDIAL GERM CELLS IN AVIANS | June 2022 | September 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17720369 | AAV VECTORS FOR VASCULAR GENE THERAPY IN CORONARY HEART DISEASE AND PERIPHERAL ISCHEMIA | April 2022 | February 2026 | Allow | 46 | 3 | 1 | No | No |
| 17642938 | ANIMAL MODEL FOR NEURODEGENERATIVE DISORDERS | March 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17642406 | METHOD OF DIFFERENTIATING PLURIPOTENT OR EPIBLAST CELLS INTO IMMATURE OOCYTES | March 2022 | November 2025 | Allow | 44 | 2 | 0 | No | No |
| 17639923 | METHODS FOR GENERATING ANIMAL MODELS FOR NONALCOHOLIC FATTY LIVER DISEASE | March 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17633668 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL2RA | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17587590 | T CELL MODIFYING COMPOUNDS AND USES THEREOF | January 2022 | October 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17515139 | PIG WITH A GENETICALLY MODIFIED CD163 GENE RESISTANT TO PRRSV | October 2021 | May 2025 | Allow | 43 | 3 | 1 | No | No |
| 17513253 | MAMMALIAN SOMATIC CELL WITH MODIFIED RNA ENCODING REPROGRAMMING FACTORS | October 2021 | March 2024 | Allow | 29 | 2 | 0 | No | No |
| 17505834 | HUMANIZED C5 ANIMALS | October 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17449374 | Method for controlling expression of a coding sequence of interest within a mammal with an inducible promoter comprising a CARE regulatory sequence | September 2021 | November 2025 | Abandon | 50 | 4 | 0 | No | No |
| 17459410 | METHOD OF USING A B4GALNT2 KNOCK OUT PIG | August 2021 | June 2025 | Allow | 46 | 2 | 0 | No | No |
| 17432364 | COMPOSITIONS AND METHODS TO TREAT BIETTI CRYSTALLINE DYSTROPHY | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17426621 | METHOD FOR PRODUCING COMPOUND WITH MODIFIED MOTHER NUCLEUS | July 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17366638 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | July 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17345773 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells | June 2021 | February 2025 | Abandon | 44 | 5 | 1 | Yes | No |
| 17298514 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | May 2021 | July 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17296000 | Food Products Comprising Avian Stem Cells | May 2021 | July 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17316060 | MAMMALIAN ALVEOLAR MACROPHAGES DERIVED FROM PLURIPOTENT CELLS | May 2021 | September 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17241763 | METHODS OF USING HUMANIZED FCyR MICE TO ASSAY Fc REGIONS | April 2021 | March 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17183263 | MINIMAL VOLUME REPROGRAMMING OF MONONUCLEAR CELLS | February 2021 | November 2024 | Allow | 45 | 2 | 0 | No | No |
| 17269897 | METHOD OF MAKING EXOSOMES FROM TUMOR CELL/ANTIGEN PRESENTING CELL HYBRID CELLS | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17168645 | GENETICALLY MODIFIED MSC AND THERAPEUTIC METHODS | February 2021 | November 2023 | Allow | 33 | 1 | 0 | No | No |
| 17159564 | GENETICALLY MODIFIED MOUSE WITH A HUMANIZED PNPLA3 GENE AND METHODS OF USE | January 2021 | November 2024 | Allow | 45 | 3 | 1 | No | No |
| 17262443 | METHOD FOR TREATING TUMOR USING IMMUNE EFFECTOR CELL | January 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17133142 | PROCESS OF TRANSFECTING PRIMORDIAL GERM CELLS IN AN AVIAN | December 2020 | October 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17131564 | GENE THERAPY FOR JUVENILE BATTEN DISEASE | December 2020 | January 2025 | Allow | 49 | 4 | 0 | Yes | No |
| 17125368 | METHOD FOR PREPARING ALZHEIMER'S DISEASE (AD) ANIMAL MODEL | December 2020 | April 2024 | Abandon | 40 | 2 | 0 | Yes | No |
| 17110868 | GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMANIZED PD1 AND PD-L1 PROTEINS | December 2020 | May 2024 | Allow | 41 | 2 | 1 | No | No |
| 15734535 | TRANSGENIC CHICKEN HAVING AN ENDOGENOUS IMMUNOGLOBULIN HEAVY CHAIN GENE IN WHICH THE IGY CH1 CODING SEQUENCE IS FUNCTIONALLY DELETED | December 2020 | November 2025 | Allow | 59 | 4 | 1 | Yes | Yes |
| 17055003 | PRODUCTS FOR THERAPY OF A MUSCULOSKELETAL CONDITION AND METHODS FOR THEIR PRODUCTION | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17081470 | GENETICALLY MODIFIED T CELL RECEPTOR MICE | October 2020 | November 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 17070276 | GENETICALLY MODIFIED CHICKEN WITH AN INACTIVATED OVOMUCOID GENE | October 2020 | June 2024 | Abandon | 44 | 3 | 0 | Yes | No |
| 17008506 | NATURAL KILLER CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR THAT BINDS CD38 | August 2020 | October 2025 | Allow | 60 | 5 | 1 | No | No |
| 16976720 | CONJUGATES COMPRISING AAVs AND CAS9 POLYPEPTIDES | August 2020 | April 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 16975422 | NUCLEOTIDE SEQUENCES ENCODING PEPTIDE LINKERS | August 2020 | February 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16970350 | PLASMID ENCODING A C-TERMINAL FRAGMENT OF PARASPECKLE COMPONENT 1 FOR TREATING TUMORS | August 2020 | December 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16939871 | Universal Human Induced Pluripotent Stem Cells And Method Of Forming The Same | July 2020 | April 2024 | Abandon | 45 | 3 | 1 | No | No |
| 16938661 | CRISPR-RELATED METHODS AND COMPOSITIONS | July 2020 | April 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16961195 | TRANSGENIC RAINBOW SHARK | July 2020 | March 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16912400 | REPROGRAMMING CELLS | June 2020 | July 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16956798 | PLACENTA-DERIVED CELL-CONDITIONED MEDIUM FOR INDUCING DEDIFFERENTIATION INTO INDUCED PLURIPOTENT STEM CELLS FROM SOMATIC CELLS AND METHOD FOR INDUCING DEDIFFERENTIATION USING THE SAME | June 2020 | March 2024 | Abandon | 44 | 3 | 1 | Yes | No |
| 16955716 | GAMETOGENESIS | June 2020 | November 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16771541 | GENETICALLY MODIFIED RAT THAT EXPRESSES AN F54L TXN1 MUTANT | June 2020 | December 2023 | Allow | 42 | 3 | 0 | Yes | No |
| 16759352 | PROCESS FOR CONTINUOUS CELL CULTURE OF GPSCS | April 2020 | October 2024 | Abandon | 54 | 2 | 1 | Yes | No |
| 16842309 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | April 2020 | July 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16835144 | HIGHLY FUNCTIONAL MANUFACTURED STEM CELLS | March 2020 | November 2024 | Abandon | 56 | 4 | 1 | No | No |
| 16651862 | FISH AND METHOD FOR PRODUCING FISH | March 2020 | February 2024 | Abandon | 47 | 4 | 0 | Yes | No |
| 16647474 | GENOME-EDITED BIRDS | March 2020 | March 2026 | Abandon | 60 | 7 | 1 | Yes | No |
| 16816826 | LOSS OF FUNCTION RODENT MODEL OF SOLUTE CARRIER 39 MEMBER 5 | March 2020 | March 2025 | Abandon | 60 | 3 | 0 | Yes | Yes |
| 16778558 | METHOD OF ENHANCING VIRAL-MEDIATED GENE DELIVERY | January 2020 | April 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16634432 | VECTOR WITH AN ENDOTHELIAL-SPECIFIC PROMOTER FOR TREATING FACTOR V, VII, VIII, OR IX DEFICIENCY | January 2020 | July 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16625999 | TRANSGENIC MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 1 | December 2019 | March 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16617787 | TRANSGENIC CHICKEN THAT EXPRESSES A FLUORESCENT PROTEIN AND SIAT1 | November 2019 | August 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16612675 | MEASURING FREQUENCY OF VARIOUS SUBSETS OF PATHOGEN-SPECIFIC T CELLS IN PERIPHERAL BLOOD AS ESTABLISHED BY VARIOUS PATTERNS OF TCR-INDUCED CA2+ SIGNALING | November 2019 | May 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16607074 | METHOD FOR GENERATING A GENETICALLY MODIFIED PIG WITH INACTIVATED PORCINE ENDOGENOUS RETROVIRUS (PERV) ELEMENTS | October 2019 | September 2023 | Allow | 47 | 3 | 0 | No | No |
| 16600117 | AGENT FOR ACCELERATING MATURATION OR AGING OF CELLS | October 2019 | October 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16499636 | TRANSGENIC RAINBOW SHARK | September 2019 | June 2024 | Abandon | 56 | 2 | 1 | No | Yes |
| 16530452 | TRANSGENIC C57BL6-BTBR MOUSE WITH A HUMANIZED MHC II GENE THAT EXPRESSES GAD65 | August 2019 | March 2024 | Allow | 55 | 4 | 1 | Yes | No |
| 16476891 | METHOD OF TRANSDIFFERENTIATING HAIR FOLLICLE STEM CELLS INTO SPERM STEM CELLS | July 2019 | October 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 16465006 | HUMANIZED MOUSE MODEL WITH IMPROVED HUMAN INNATE IMMUNE CELL DEVELOPMENT | May 2019 | October 2025 | Abandon | 60 | 8 | 1 | No | No |
| 16461533 | METHOD OF ISOLATING MYOGENIC PROGENITORS USING CD54 | May 2019 | October 2025 | Allow | 60 | 9 | 0 | Yes | No |
| 16361873 | TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES | March 2019 | March 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WILSON, MICHAEL C.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WILSON, MICHAEL C works in Art Unit 1638 and has examined 194 patent applications in our dataset. With an allowance rate of 79.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner WILSON, MICHAEL C's allowance rate of 79.4% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WILSON, MICHAEL C receive 3.07 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WILSON, MICHAEL C is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -1.5% benefit to allowance rate for applications examined by WILSON, MICHAEL C. This interview benefit is in the 10% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 43.5% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 45.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 90.2% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 17.5% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.